Sat, Jul 26, 2014, 11:11 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

InVivo Therapeutics Holdings Corp. Message Board

  • factman777 factman777 Oct 10, 2012 10:52 PM Flag

    Update: Oct. 10, 2012. Just the facts…Part 3

    Fact 11: InVivo has Bob Langer, Sc.D. on their team. Robert S. Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT) (being an Institute Professor is the highest honor that can be awarded to a faculty member). Dr. Langer has written over 1,100 articles. He also has approximately 760 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 220 pharmaceutical, chemical, biotechnology and medical device companies.

    He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 — 2002 and as its Chairman from 1999- 2002.

    His experience at the FDA should not be underestimated. He was instrumental in convincing the FDA to allow InVivo’s polymer-based medical treatments to proceed along the Humanitarian Use Device/Humanitarian Device Exemption pathway with just an initial 5 patient clinical trial. See Fact 5 above.

    Fact 12: Frank Reynolds is an extremely driven CEO that is passionate about helping people with Spinal Cord injuries. Mr. Reynolds suffered a paralyzing injury to his spine in December 1992. He spent 5 years of his life in bed paralyzed, except for some small movement in his legs, but only when he laid down. He could not walk. While recovering from this injury he spent several years gaining subject matter expertise on the spine and spinal cord.

    Fact 13: InVivo raised $20 million in early 2012 from a select group of institutional investors and has $18.0 million of cash on hand as of June 30, 2012. This is sufficient to fund operations well into 2014. Exercise of warrants also has the potential to raise an additional $16.7 million of cash.

    As I said before: just the facts.

    -FactMan777

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thanks for pointing out the powerful and successful scientific leadership of NVIV:
      Your point -
      Langer has patents that were licensed to more than 220 pharmaceutical, chemical, biotechnology and medical device companies. Yes that is 220 patent licenses - no decimal place mistake.

      Langer served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 — 2002 and as its Chairman from 1999- 2002.

      Yes, Langer was Chairman of the FDA's Science board, their highest level advisory board, from 1999 to 2002.

 
NVIV
0.95-0.01(-1.04%)Jul 25 3:53 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.